LAUNXP Biomedical Co., Ltd
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect tre… Read more
LAUNXP Biomedical Co., Ltd (6876) - Total Liabilities
Latest total liabilities as of June 2025: NT$282.86 Million TWD
Based on the latest financial reports, LAUNXP Biomedical Co., Ltd (6876) has total liabilities worth NT$282.86 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LAUNXP Biomedical Co., Ltd - Total Liabilities Trend (2021–2024)
This chart illustrates how LAUNXP Biomedical Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LAUNXP Biomedical Co., Ltd Competitors by Total Liabilities
The table below lists competitors of LAUNXP Biomedical Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scores Hldg Co Inc
PINK:SCRH
|
USA | $697.15K |
|
ABAS Protect AB
ST:ABAS
|
Sweden | Skr44.16 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down LAUNXP Biomedical Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LAUNXP Biomedical Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LAUNXP Biomedical Co., Ltd (2021–2024)
The table below shows the annual total liabilities of LAUNXP Biomedical Co., Ltd from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$15.05 Million | -35.13% |
| 2023-12-31 | NT$23.19 Million | +126.72% |
| 2022-12-31 | NT$10.23 Million | +18.29% |
| 2021-12-31 | NT$8.65 Million | -- |